Case Studies
Turning Access Signals Into Prescriptions...
November 3, 2025
In this use case, learn how one pharma company uses real-world data triggers about patient-level events to improve sales prioritization and pull-through.
Spotlight Resources
Infographics
Connecting Patients to Coverage via...
November 3, 2025
Learn how pharma and healthcare IT companies can determine coverage details for individual patients with MMIT’s Bridging as a Service and Coverage API. This infographic shows how prescription BIN/PCN/Group (BPG) data serves as the anchor key to unlock coverage clarity.
Case Studies
Reducing Denials with MMIT’s Coverage...
November 3, 2025
In this use case, learn how one pharma company used coverage data plus real-world data signals from claims, labs, and EMR systems to better understand the connection between payer coverage and claims. After identifying missing billing codes as the primary driver of denials, the company launched an HCP education campaign to help resolve the access […]
Case Studies
Connect Payer Policy to Patient...
November 3, 2025
In this use case, learn how one pharma company persuaded payers to ease restrictions on its neurological therapy using real-world data signals and market research. By integrating RWD from claims, lab, and EMR data into Message Monitor results, the company showed the impact of evolving payer sentiment on providers’ prescribing behavior.
Ebook
Unlocking Patient Access: How Rx...
October 8, 2025
In this ebook, learn how mapping Rx BIN/PCN/Group (BPG) data to coverage data can help healthcare IT companies streamline early benefit verification for their clients.
Case Studies
HIT Company Streamlines Benefit Verification...
October 7, 2025
In this case study, learn how one healthcare IT company used Rx BIN/PCN/Group data to provide its physician clients with accurate, patient-specific coverage details for certain therapies.
Case Studies
Strategic Launch Report With In-Depth...
June 6, 2022
Learn how a pharma company leveraged MMIT’s Strategic Launch Report combined with In-Depth Interviews to get a unique view into the market access path for its therapy.